NO20071428L - Kombinasjon inneholdende ZD6474 og Imatinib - Google Patents
Kombinasjon inneholdende ZD6474 og ImatinibInfo
- Publication number
- NO20071428L NO20071428L NO20071428A NO20071428A NO20071428L NO 20071428 L NO20071428 L NO 20071428L NO 20071428 A NO20071428 A NO 20071428A NO 20071428 A NO20071428 A NO 20071428A NO 20071428 L NO20071428 L NO 20071428L
- Authority
- NO
- Norway
- Prior art keywords
- imatinib
- human
- angiogenic
- warm
- producing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0421438A GB0421438D0 (en) | 2004-09-27 | 2004-09-27 | Combination therapy |
GB0506726A GB0506726D0 (en) | 2005-04-01 | 2005-04-01 | Combination therapy |
PCT/GB2005/003673 WO2006035204A2 (en) | 2004-09-27 | 2005-09-23 | Combination comprising zd6474 and an imatinib |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20071428L true NO20071428L (no) | 2007-04-02 |
Family
ID=35924044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20071428A NO20071428L (no) | 2004-09-27 | 2007-03-16 | Kombinasjon inneholdende ZD6474 og Imatinib |
Country Status (11)
Country | Link |
---|---|
US (2) | US20080119479A1 (es) |
EP (1) | EP1804802A2 (es) |
JP (1) | JP2008514577A (es) |
KR (1) | KR20070072543A (es) |
AU (1) | AU2005288737B2 (es) |
BR (1) | BRPI0516052A (es) |
CA (1) | CA2578956A1 (es) |
IL (1) | IL181609A0 (es) |
MX (1) | MX2007003505A (es) |
NO (1) | NO20071428L (es) |
WO (1) | WO2006035204A2 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
PT1592423E (pt) * | 2003-02-13 | 2011-06-16 | Astrazeneca Ab | Terapia de combinação de zd6474 com 5-fu e/ou cpt-11 |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
CA2531862C (en) * | 2003-07-10 | 2011-10-25 | Astrazenca Ab | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
SI1971338T1 (sl) * | 2005-12-22 | 2011-06-30 | Astrazeneca Ab | Kombinacija ZD6474 in pemetrekseda |
EP2066353B1 (en) * | 2006-09-29 | 2013-01-02 | AstraZeneca AB | Combination of zd6474 and bevacizumab for cancer therapy |
EP2252955A1 (en) | 2008-03-03 | 2010-11-24 | Nike International Ltd. | Interactive athletic equipment system |
US8231506B2 (en) | 2008-12-05 | 2012-07-31 | Nike, Inc. | Athletic performance monitoring systems and methods in a team sports environment |
US8628453B2 (en) | 2008-12-05 | 2014-01-14 | Nike, Inc. | Athletic performance monitoring systems and methods in a team sports environment |
US20100184564A1 (en) | 2008-12-05 | 2010-07-22 | Nike, Inc. | Athletic Performance Monitoring Systems and Methods in a Team Sports Environment |
KR101926319B1 (ko) | 2010-11-10 | 2018-12-06 | 나이키 이노베이트 씨.브이. | 시간 기반 체육 활동 측정 및 표시를 위한 시스템 및 방법 |
KR101810751B1 (ko) | 2011-02-17 | 2017-12-19 | 나이키 이노베이트 씨.브이. | 물리적 활동 데이터와 영상 데이터간의 선택 및 상관 |
KR101386697B1 (ko) * | 2012-06-18 | 2014-04-18 | 아주대학교산학협력단 | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
WO2015017728A1 (en) | 2013-07-31 | 2015-02-05 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
KR101778004B1 (ko) | 2015-06-22 | 2017-09-15 | (주) 에빅스젠 | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 |
CN111278466A (zh) | 2017-07-26 | 2020-06-12 | 夫特弗制药私人有限公司 | 伊马替尼的液体剂型 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL203782B1 (pl) * | 1999-11-05 | 2009-11-30 | Astrazeneca Ab | Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
AU2003231098A1 (en) * | 2002-04-25 | 2003-11-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
CA2495487A1 (en) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
PT1592423E (pt) * | 2003-02-13 | 2011-06-16 | Astrazeneca Ab | Terapia de combinação de zd6474 com 5-fu e/ou cpt-11 |
CA2531862C (en) * | 2003-07-10 | 2011-10-25 | Astrazenca Ab | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
AU2005288736B2 (en) * | 2004-09-27 | 2008-08-14 | Astrazeneca Ab | Cancer combination therapy comprising AZD2171 and imatinib |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
SI1971338T1 (sl) * | 2005-12-22 | 2011-06-30 | Astrazeneca Ab | Kombinacija ZD6474 in pemetrekseda |
-
2005
- 2005-09-23 JP JP2007532963A patent/JP2008514577A/ja active Pending
- 2005-09-23 MX MX2007003505A patent/MX2007003505A/es not_active Application Discontinuation
- 2005-09-23 KR KR1020077009369A patent/KR20070072543A/ko not_active Application Discontinuation
- 2005-09-23 WO PCT/GB2005/003673 patent/WO2006035204A2/en active Application Filing
- 2005-09-23 BR BRPI0516052-9A patent/BRPI0516052A/pt not_active IP Right Cessation
- 2005-09-23 US US11/663,913 patent/US20080119479A1/en not_active Abandoned
- 2005-09-23 AU AU2005288737A patent/AU2005288737B2/en not_active Ceased
- 2005-09-23 EP EP05786268A patent/EP1804802A2/en not_active Withdrawn
- 2005-09-23 CA CA002578956A patent/CA2578956A1/en not_active Abandoned
-
2007
- 2007-02-27 IL IL181609A patent/IL181609A0/en unknown
- 2007-03-16 NO NO20071428A patent/NO20071428L/no not_active Application Discontinuation
-
2009
- 2009-06-05 US US12/479,131 patent/US20100069398A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100069398A1 (en) | 2010-03-18 |
MX2007003505A (es) | 2007-05-10 |
AU2005288737B2 (en) | 2008-08-14 |
BRPI0516052A (pt) | 2008-08-19 |
JP2008514577A (ja) | 2008-05-08 |
US20080119479A1 (en) | 2008-05-22 |
CA2578956A1 (en) | 2006-04-06 |
AU2005288737A1 (en) | 2006-04-06 |
WO2006035204A3 (en) | 2006-10-19 |
WO2006035204A2 (en) | 2006-04-06 |
IL181609A0 (en) | 2007-07-04 |
EP1804802A2 (en) | 2007-07-11 |
KR20070072543A (ko) | 2007-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20071428L (no) | Kombinasjon inneholdende ZD6474 og Imatinib | |
NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
NO20050528L (no) | Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft | |
NO20072167L (no) | Kombinasjon omfattende ZD6474 og et antiandrogen | |
DK1551409T3 (da) | Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer | |
CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
NO20056170L (no) | Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839 | |
NO20064753L (no) | Kombinasjonsterapi | |
NO20076657L (no) | Kombinasjonsterapi av cancer med AZD2171 og gemcitabin | |
HK1096023A1 (en) | Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11 | |
BR0309226A (pt) | Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável | |
NO20064754L (no) | Kombinasjonsterapi | |
HK1074840A1 (en) | Novel dithiolopyrrolones with therapeutic activity | |
NO20051601L (no) | Kombinasjonsterapi med gemcitabin og zd6126 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |